Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Tactical Therapeutics, Inc.
Sponsor:
Information provided by (Responsible Party):
Tactical Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01107522
First received: April 16, 2010
Last updated: July 10, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid tumors; in combination with oral Temodar® in patients with glioblastoma or other recurrent malignant gliomas; or in combination with oral Temodar® and radiation therapy in patients with newly diagnosed glioblastoma or other malignant gliomas.


Condition Intervention Phase
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Drug: CTO
Drug: CTO and Temodar®
Drug: CTO, Temodar®, Radiation therapy
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study of Oral Carboxyamidotriazole Orotate (CTO) Titrated as a Single Agent in Patients With Advanced or Metastatic Solid Tumors and Titrated in Combination Therapy With Temodar® for Patients With Glioblastoma and Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas

Resource links provided by NLM:


Further study details as provided by Tactical Therapeutics, Inc.:

Primary Outcome Measures:
  • To determine the MTD/RD of single agent CTO in patients with advanced or metastatic solid tumors; or CTO in combination with Temodar® in patients with glioblastoma or other recurrent malignant gliomas [ Time Frame: Duration of the study ] [ Designated as safety issue: Yes ]
    To determine the highest tolerated dose of CTO, based on safety data and occurence of dose-limiting toxicity, in patients with advanced or metastatic solid tumors. In the second stage of the study, to determine the highest tolerated dose of CTO in combination with Temodar®, based on safety data and toxicity profile, in patients with glioblastoma or other recurrent malignant gliomas. In the third stage of the study, to determine the highest tolerated dose of CTO in combination with Temodar® and radiation therapy based on safety data and toxicity profile, in patients with newly diagnosed glioblastoma or other malignant gliomas.


Secondary Outcome Measures:
  • Preliminary tumor response [ Time Frame: after every 2 cycles ] [ Designated as safety issue: No ]
    RECIST 1.1 (Arm A); Macdonald Criteria (Arms B and C)

  • Pharmacokinetics (maximum concentration, Tmax, AUC, T1/2, clearance, volume of distribution) [ Time Frame: pre- and post-dose during cycle 1 ] [ Designated as safety issue: No ]
    Plasma concentrations and PK parameters will be determined for single agent CTO (Arm A), or CTO in combination with Temodar® (Arm B); plasma concentrations and PK parameters will be determined for Temodar®, or CTO and Temodar® in combination with radiation therapy (Arm C).

  • Voluntary Exploratory objective [ Time Frame: collected prior to enrollment ] [ Designated as safety issue: No ]
    To investigate effect of CTO on tumor growth based on genotype

  • Exploratory Objective [ Time Frame: Duration of study ] [ Designated as safety issue: No ]
    To investigate effect of CTO alone and in combination with Temodar® on gene expression in scalp hair


Study Start Date: May 2010
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Single Agent CTO
Drug: CTO
Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
Experimental: Arm B
Combination CTO and Temodar®
Drug: CTO and Temodar®

Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.

Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.

Experimental: Arm C
Combination CTO, Temodar®, Radiation therapy
Drug: CTO, Temodar®, Radiation therapy
Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Treatment Arm A)

  1. Patients must have histologically-confirmed solid tumors that are advanced or metastatic, and refractory after standard therapy, or for which there is no standard therapy.
  2. Patients must have measurable disease as defined by RECIST version 1.1.
  3. Patients must have received prior anticancer therapy or not be eligible for any established conventional therapy whether surgical or pharmacologic.
  4. Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <=grade 1 prior to study entry.
  5. Patients must have a performance status of 0, 1, or 2.
  6. Patients must be men and women >=18 years of age.
  7. Patients must have adequate bone marrow function, defined as an absolute neutrophil count >=1.5 x 10^9/L and a platelet count >= 100 x 10^9/L.
  8. Patients must have adequate renal function, defined as serum creatinine <= 1.2 mg/dL (if > 1.2 mg/dL, a calculated creatinine clearance [by the Cockcroft-Gault method] must be >=60 mL/min/1.73 m^2).
  9. Patients must have adequate hepatic function, defined as plasma total bilirubin <=1.5 mg, alanine transaminase (ALT) and aspartate transaminase (AST) <=2.5 X ULN. Patients with Gilbert's disease outside these limits are judged to be ineligible.
  10. Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
  11. Patients with reproductive potential must agree to use at least one form of barrier contraception prior to study entry and for up to 30 days beyond the last administration of study drug.
  12. Patients must be judged to be capable by the Investigator of providing informed consent and must be willing to provide written informed consent prior to the start of any study specific procedures.
  13. Patients should have a life expectancy of at least 12 weeks.

Exclusion Criteria (Treatment Arm A)

  1. Patients may not have had prior chemotherapy, hormonal therapy, radiation therapy, or biologic therapy in the 4 weeks prior to study entry with the exception of mitomycin C or nitrosoureas, for which patients must be 6 weeks from prior treatment. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study.
  2. Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following:

    • Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or dysrhythmias.
    • Active infection.
    • Unstable diabetes mellitus
    • Psychiatric disorder that may interfere with consent and/or protocol compliance.
  3. Pregnant or breastfeeding women.
  4. Patients with another malignancy in the past 3 years except: curatively treated non-melanoma skin cancer; or carcinoma in situ, of either cervix or breast, that does not require further treatment.
  5. Patients with known HIV, HBV, or HCV infection.
  6. Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
  7. Patients with central nervous system metastases. Baseline CT or MRI scan of brain is required only in the case of clinical suspicion of central nervous system metastases. Patients with evidence of brain involvement, leptomeningeal disease, or seizure disorder are also excluded.
  8. Patients may not be treated with known CYP3A4 inhibitors or inducers.

Inclusion and Exclusion Criteria for Combination CTO Plus Temodar® (Treatment Arm B): Inclusion Criteria (Treatment Arm B)

In addition to the inclusion criteria for adequate organ function as defined for the patients with advanced or metastatic solid tumors, patients enrolled in Arm B (Combination Therapy CTO Plus Temodar-R) must meet the following inclusion criteria:

  1. Patients must have histologically proven malignant glioblastoma or other recurrent malignant gliomas.
  2. Measurable tumor must be present on gadolinium-enhanced MRI.
  3. Patients must have a life expectancy of at least 8 weeks.
  4. Patients must have a Performance Status of 0, 1, or 2 (ECOG scale).
  5. Patients must be men and women >=18 years of age.
  6. Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or <=grade 1 prior to study entry.
  7. Patients must have shown unequivocal radiographic evidence for tumor progression by MRI scan to be performed within 14 days prior to registration and must be on a steroid dose that has been stable for at least 5 days. If the steroid dose is increased between the date of imaging and registration, a new baseline MRI scan is required.
  8. Patients who have undergone recent resection for recurrent or progressive malignant tumor will be eligible as long as all of the following conditions apply:

    1. They have recovered from the effects of surgery
    2. The extent of residual disease is assessed post-operatively, with an MRI scan done no later than 96 hours in the immediate post-operative period or at least 4 weeks post-operatively, within 14 days prior to registration. If the 96-hour scan is more than 14 days before registration, the scan needs to be repeated.
  9. Patients must have had prior radiation therapy with or without chemotherapy and must have progressed following radiation therapy and must have an interval of >=12 weeks from the completion of radiation therapy to registration date to minimize the possibility of pseudo-progression.
  10. Patients under treatment with anti-epileptic drugs which are not known CYP3A4 inhibitors or inducers must have been receiving a stable dose for at least 2 weeks with no evidence of seizures at the time of registration.

Exclusion Criteria (Treatment Arm B)

  1. Patients may not have had prior chemotherapy, hormonal therapy, or biologic therapy in the 4 weeks prior to study entry with the exception of mitomycin C or nitrosoureas, for which patients must be 6 weeks from prior treatment. For patients who have been treated with targeted therapy, 5 half-lives of that therapy (or 28 days, whichever is shorter) must have passed prior to enrollment in the study. Additional exceptions: The following specific drugs are permitted shorter recovery times: 14 days for vincristine, 21 days for procarbazine, and 7 days for non-cytotoxic agents such as interferon, tamoxifen, thalidomide, and cis-retinoic acid.
  2. Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following:

    • Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or dysrhythmias.
    • Active infection.
    • Unstable diabetes mellitus.
    • Psychiatric disorder that may interfere with consent and/or protocol compliance.
  3. Pregnant or breastfeeding women.
  4. Patients with another malignancy in the past 3 years except: curatively treated non-melanoma skin cancer; or carcinoma in situ, of either cervix or breast, that does not require further treatment.
  5. Patients with known HIV, HBV, or HCV infection.
  6. Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
  7. Uncontrolled seizure activity.
  8. Patients may not be treated with known CYP3A4 inhibitors or inducers.

Inclusion and Exclusion Criteria for Combination CTO and Temodar® in combination with radiation therapy (Treatment Arm C):

Inclusion Criteria (Treatment Arm C)

In addition to the inclusion criteria for adequate organ function as defined for the patients with advanced or metastatic solid tumors, patients enrolled in Arm C (Combination Therapy CTO and Temodar® in combination with radiation therapy) must meet the following inclusion criteria:

  1. Patients must have histologically proven newly diagnosed glioblastoma or other malignant gliomas. Note: Patients with anaplastic oligodendroglioma with 1p/19q deletion or unknown 1p/19q status are not eligible
  2. Patients must have a life expectancy of at least 8 weeks
  3. Patients must have a Performance Status of 0, 1, or 2 (ECOG scale).
  4. Patients must be men and women >=18 years of age.
  5. Patients must have undergone an MRI scan performed within 14 days prior to registration and must be on a steroid dose that has been stable for at least 5 days. If the steroid dose is increased between the date of imaging and registration, a new baseline MRI is required.
  6. Patients under treatment with anti-epileptic drugs which are not known CYP3A4 inhibitors or inducers must have been receiving a stable dose for at least 2 weeks with no evidence of seizures at the time of registration.

Exclusion Criteria (Treatment Arm C)

  1. Patients may not have had any prior chemotherapy, hormonal therapy, or biologic therapy for gliomas.
  2. Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following:

    • Congestive heart failure or uncontrolled angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension, or dysrhythmias.
    • Active infection.
    • Unstable diabetes mellitus.
    • Psychiatric disorder that may interfere with consent and/or protocol compliance.
  3. Pregnant or breastfeeding women.
  4. Patients with another malignancy in the past 3 years except: curatively treated non-melanoma skin cancer; or carcinoma in situ, of either cervix or breast, that does not require further treatment.
  5. Patients with known HIV, HBV, or HCV infection.
  6. Patients with an underlying diagnosis or disease state associated with an increased risk of bleeding.
  7. Uncontrolled seizure activity.
  8. Patients may not be treated with known CYP3A4 inhibitors or inducers.
  9. Patients with anaplastic oligodendroglioma with 1p/19q deletion or unknown 1p/19q status are excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01107522

Locations
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10017
Contact: Dylan Bobrow    646-227-2610    bobrowd@mskcc.org   
Principal Investigator: Antonio Omuro, MD         
New York University Recruiting
New York, New York, United States, 10016
Contact: Denise Rodriguez    212-263-8210    denise.rodriguez@nyumc.org   
Principal Investigator: Katharine McNeill, MD         
United States, Oregon
Providence Cancer Center Recruiting
Portland, Oregon, United States, 97213
Contact: Chris Fountain, BSN    503-215-2691    christopher.fountain@providence.org   
Principal Investigator: Walter Urba, MD, PhD         
Oregon Health and Sciences University Recruiting
Portland, Oregon, United States, 97239
Contact: Knight Clinical Trials Information Line    503-494-1080      
Principal Investigator: Matthew Taylor, MD         
Switzerland
Zurich University Hospital Not yet recruiting
Zurich, Switzerland
Contact: Roger Stupp, MD    41-44-255-1735      
Sponsors and Collaborators
Tactical Therapeutics, Inc.
Investigators
Principal Investigator: Matthew Taylor, MD Oregon Health and Sciences University
Principal Investigator: Antonio Omuro, MD Memorial Sloan-Kettering Cancer Center
Investigator: Walter Urba, MD, PhD Providence Health & Services
Investigator: Katharine McNeill, MD NYU MEDICAL CENTER
Investigator: Roger Stupp, MD Zurich University Hospital
  More Information

No publications provided

Responsible Party: Tactical Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01107522     History of Changes
Other Study ID Numbers: T09-10644
Study First Received: April 16, 2010
Last Updated: July 10, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms
Glioblastoma
Glioma
Astrocytoma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Carboxyamido-triazole
Temozolomide
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Antineoplastic Agents, Alkylating
Alkylating Agents

ClinicalTrials.gov processed this record on October 19, 2014